Table of Contents
International Journal of Proteomics
Volume 2012 (2012), Article ID 876401, 15 pages
http://dx.doi.org/10.1155/2012/876401
Review Article

Application of Proteomics to Soft Tissue Sarcomas

1Division of Pharmacoproteomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Received 29 February 2012; Accepted 21 April 2012

Academic Editor: Ákos Végvári

Copyright © 2012 Tadashi Kondo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. W. Weiss and J. R. Goldblum, Soft Tissue Tumors, Mosby, 2007.
  2. G. D. Demetri, M. Von Mehren, C. D. Blanke et al., “Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors,” New England Journal of Medicine, vol. 347, no. 7, pp. 472–480, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar
  4. J. M. Coindre, I. Hostein, G. Maire et al., “Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity,” Journal of Pathology, vol. 203, no. 3, pp. 822–830, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Idbaih, J. M. Coindre, J. Derré et al., “Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances,” Laboratory Investigation, vol. 85, no. 2, pp. 176–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. T. O. Nielsen, R. B. West, S. C. Linn et al., “Molecular characterisation of soft tissue tumours: a gene expression study,” The Lancet, vol. 359, no. 9314, pp. 1301–1307, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Terry, T. Saito, S. Subramanian et al., “TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies,” American Journal of Surgical Pathology, vol. 31, no. 2, pp. 240–246, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Wachtel, T. Runge, I. Leuschner et al., “Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 816–822, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. R. B. West, C. L. Corless, X. Chen et al., “The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status,” American Journal of Pathology, vol. 165, no. 1, pp. 107–113, 2004. View at Google Scholar · View at Scopus
  10. R. B. West, J. Harvell, S. C. Linn et al., “Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans,” American Journal of Surgical Pathology, vol. 28, no. 8, pp. 1063–1069, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Gry, R. Rimini, S. Strömberg et al., “Correlations between RNA and protein expression profiles in 23 human cell lines,” BMC Genomics, vol. 10, article 365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Chen, T. G. Gharib, C. C. Huang et al., “Discordant protein and mRNA expression in lung adenocarcinomas,” Molecular & Cellular Proteomics, vol. 1, no. 4, pp. 304–313, 2002. View at Google Scholar · View at Scopus
  13. B. Schwanhüusser, D. Busse, N. Li et al., “Global quantification of mammalian gene expression control,” Nature, vol. 473, no. 7347, pp. 337–342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. D. Tipton, J. C. Tran, A. D. Catherman, D. R. Ahlf, K. R. Durbin, and N. L. Kelleher, “Analysis of intact protein isoforms by mass spectrometry,” Journal of Biological Chemistry, vol. 286, no. 29, pp. 25451–25458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Hasegawa, S. Yamamoto, T. Nojima et al., “Validity and reproducibility of histologic diagnosis and grading for adult soft-tissue sarcomas,” Human Pathology, vol. 33, no. 1, pp. 111–115, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Suehara, T. Kondo, K. Fujii et al., “Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas,” Proteomics, vol. 6, no. 15, pp. 4402–4409, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. W. O. Russell, J. Cohen, and F. Enzinger, “A clinical and pathological staging system for soft tissue sarcomas,” Cancer, vol. 40, no. 4, pp. 1562–1570, 1977. View at Google Scholar · View at Scopus
  18. H. Hashimoto and M. Enjoji, “Liposarcoma. A clinicopathologic subtyping of 52 cases,” Acta Pathologica Japonica, vol. 32, no. 6, pp. 933–948, 1982. View at Google Scholar · View at Scopus
  19. D. Cervi, T. T. Yip, N. Bhattacharya et al., “Platelet-associated PF-4 as a biomarker of early tumor growth,” Blood, vol. 111, no. 3, pp. 1201–1207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Taylor and J. Folkman, “Protamine is an inhibitor of angiogenesis,” Nature, vol. 297, no. 5864, pp. 307–312, 1982. View at Google Scholar · View at Scopus
  21. T. E. Maione, G. S. Gray, J. Petro et al., “Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides,” Science, vol. 247, no. 4938, pp. 77–79, 1990. View at Google Scholar · View at Scopus
  22. H. Joensuu and L. G. Kindblom, “Gastrointestinal stromal tumors—a review,” Acta Orthopaedica Scandinavica, Supplement, vol. 75, no. 311, pp. 62–71, 2004. View at Google Scholar · View at Scopus
  23. M. Miettinen, W. El-Rifai, L. Sobin, and J. Lasota, “Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review,” Human Pathology, vol. 33, no. 5, pp. 478–483, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. J. J. Rumessen, S. Peters, and L. Thuneberg, “Light- and electron microscopical studies of interstitial cells of Cajal and muscle cells at the submucosal border of human colon,” Laboratory Investigation, vol. 68, no. 4, pp. 481–495, 1993. View at Google Scholar · View at Scopus
  25. J. H. Zhong, L. Ma, L. Q. Li, H. M. Ru, and Y. N. Zhao, “Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems,” Scandinavian Journal of Gastroenterology, vol. 46, no. 6, pp. 645–651, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R. P. DeMatteo, K. V. Ballman, C. R. Antonescu et al., “Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 373, no. 9669, pp. 1097–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Y. Blay, M. Von Mehren, and M. E. Blackstein, “Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors,” Cancer, vol. 116, no. 22, pp. 5126–5137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Suehara, T. Kondo, K. Seki et al., “Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics,” Clinical Cancer Research, vol. 14, no. 6, pp. 1707–1717, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. B. L. Resendes, S. F. Kuo, N. G. Robertson et al., “Isolation from cochlea of a novel human intronless gene with predominant fetal expression,” Journal of the Association for Research in Otolaryngology, vol. 5, no. 2, pp. 185–202, 2004. View at Google Scholar · View at Scopus
  30. J. Schwenk, M. Metz, G. Zolles et al., “Native GABAB receptors are heteromultimers with a family of auxiliary subunits,” Nature, vol. 465, no. 7295, pp. 231–235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Kikuta, M. Gotoh, T. Kanda et al., “Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities,” Japanese Journal of Clinical Oncology, vol. 40, no. 1, Article ID hyp125, pp. 60–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Kubota, H. Orita, A. Yoshida et al., “Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities,” Japanese Journal of Clinical Oncology, vol. 41, no. 10, Article ID hyr121, pp. 1194–1202, 2011. View at Publisher · View at Google Scholar
  33. T. Kondo and S. Hirohashi, “Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics,” Nature protocols, vol. 1, no. 6, pp. 2940–2956, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Kikuta, D. Kubota, T. Saito et al., “Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor,” Journal of Proteomics, vol. 75, no. 4, pp. 1089–1098, 2012. View at Publisher · View at Google Scholar
  35. T. Sugiura, K. Sakurai, and Y. Nagano, “Intracellular characterization of DDX39, a novel growth-associated RNA helicase,” Experimental Cell Research, vol. 313, no. 4, pp. 782–790, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Sugiura, Y. Nagano, and Y. Noguchi, “DDX39, upregulated in lung squamous cell cancer, displays RNA helicase activities and promotes cancer cell growth,” Cancer Biology and Therapy, vol. 6, no. 6, pp. 957–964, 2007. View at Google Scholar · View at Scopus
  37. H. H. Yoo and I. K. Chung, “Requirement of DDX39 DEAD box RNA helicase for genome integrity and telomere protection,” Aging Cell, vol. 10, no. 4, pp. 557–571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. T. S. Emory, L. H. Sobin, L. Lukes, D. H. Lee, and T. J. O'Leary, “Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site,” American Journal of Surgical Pathology, vol. 23, no. 1, pp. 82–87, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. C. D. M. Fletcher, J. J. Berman, C. Corless et al., “Diagnosis of gastrointestinal stromal tumors: a consensus approach,” Human Pathology, vol. 33, no. 5, pp. 459–465, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Suehara, K. Kikuta, R. Nakayama et al., “Anatomic site-specific proteomic signatures of gastrointestinal stromal tumors,” Proteomics, vol. 3, no. 5, pp. 584–596, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Hashimoto, Y. Daimaru, M. Tsuneyoshi, and M. Enjoji, “Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study,” Cancer, vol. 57, no. 10, pp. 2077–2088, 1986. View at Google Scholar · View at Scopus
  42. J. Yang, J. A. Eddy, Y. Pan et al., “Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug,” Molecular and Cellular Proteomics, vol. 9, no. 11, pp. 2405–2413, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. S. C. Abraham, “Distinguishing gastrointestinal stromal tumors from their mimics: an update,” Advances in Anatomic Pathology, vol. 14, no. 3, pp. 178–188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Wells, C. Yates, and C. R. Shepard, “E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas,” Clinical and Experimental Metastasis, vol. 25, no. 6, pp. 621–628, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Dhingra, M. E. Rodriguez, Q. Shen et al., “Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 2, pp. 134–146, 2011. View at Google Scholar · View at Scopus
  46. B. Edris, I. Espinosa, T. Mühlenberg et al., “ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour,” Journal of Pathology, vol. 227, no. 2, pp. 223–233, 2012. View at Publisher · View at Google Scholar
  47. A. H. Beck, C. H. Lee, D. M. Witten et al., “Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling,” Oncogene, vol. 29, no. 6, pp. 845–854, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Dagher and L. Helman, “Rhabdomyosarcoma: an overview,” Oncologist, vol. 4, no. 1, pp. 34–44, 1999. View at Google Scholar · View at Scopus
  49. G. Merlino and L. J. Helman, “Rhabdomyosarcoma—working out the pathways,” Oncogene, vol. 18, no. 38, pp. 5340–5348, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. S. L. Spunt, L. M. Smith, F. B. Ruymann et al., “Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group,” Clinical Cancer Research, vol. 10, no. 18 I, pp. 6072–6079, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. W. M. Crist, J. R. Anderson, J. L. Meza et al., “Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease,” Journal of Clinical Oncology, vol. 19, no. 12, pp. 3091–3102, 2001. View at Google Scholar · View at Scopus
  52. J. G. Pressey, C. S. Pressey, G. Robinson et al., “2D-difference gel electrophoretic proteomic analysis of a cell culture model of alveolar rhabdomyosarcoma,” Journal of Proteome Research, vol. 10, no. 2, pp. 624–636, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. E. F. Petricoin, V. Espina, R. P. Araujo et al., “Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival,” Cancer Research, vol. 67, no. 7, pp. 3431–3440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. C. A. Clifford, A. J. Mackin, and C. J. Henry, “Treatment of canine hemangiosarcoma: 2000 and beyond,” Journal of Veterinary Internal Medicine, vol. 14, no. 5, pp. 479–485, 2000. View at Google Scholar · View at Scopus
  55. A. N. Smith, “Hemangiosarcoma in dogs and cats,” Veterinary Clinics of North America, vol. 33, no. 3, pp. 533–552, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. P. C. Schultheiss, “A retrospective study of visceral and nonvisceral hemangiosarcoma and hemangiomas in domestic animals,” Journal of Veterinary Diagnostic Investigation, vol. 16, no. 6, pp. 522–526, 2004. View at Google Scholar · View at Scopus
  57. G. M. Kirby, A. Mackay, A. Grant et al., “Concentration of lipocalin region of collagen XXVII Alpha 1 in the serum of dogs with hemangiosarcoma,” Journal of Veterinary Internal Medicine, vol. 25, no. 3, pp. 497–503, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. R. J. Young, N. J. Brown, M. W. Reed, D. Hughes, and P. J. Woll, “Angiosarcoma,” The Lancet Oncology, vol. 11, no. 10, pp. 983–991, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Lynen, M. Zolfo, V. Huyst et al., “Management of Kaposi's sarcoma in resource-limited settings in the era of HAART,” AIDS Reviews, vol. 7, no. 1, pp. 13–21, 2005. View at Google Scholar · View at Scopus
  60. R. A. Schwartz, “Kaposi's sarcoma: an update,” Journal of Surgical Oncology, vol. 87, no. 3, pp. 146–151, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Kang, F. C. Ye, S. J. Gao, and L. D. Wang, “Angiogenesis, Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus,” Virologica Sinica, vol. 23, no. 6, pp. 449–458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. F. X. Zhu, J. M. Chong, L. Wu, and Y. Yuan, “Virion proteins of Kaposi's sarcoma-associated herpesvirus,” Journal of Virology, vol. 79, no. 2, pp. 800–811, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. J. E. Jong, J. Park, S. Kim, and T. Seo, “Kaposi's sarcoma-associated herpesvirus viral protein kinase interacts with RNA helicase a and regulates host gene expression,” Journal of Microbiology, vol. 48, no. 2, pp. 206–212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Kaul, S. C. Verma, and E. S. Robertson, “Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA,” Virology, vol. 364, no. 2, pp. 317–329, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. E. Bartee, A. McCormack, and K. Früh, “Quantitative membrane proteomics reveals new cellular targets of viral immune modulators,” PLoS pathogens, vol. 2, no. 10, p. e107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. S. E. Ong, B. Blagoev, I. Kratchmarova et al., “Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics,” Molecular & Cellular Proteomics, vol. 1, no. 5, pp. 376–386, 2002. View at Google Scholar · View at Scopus
  67. P. Uetz, Y. A. Dong, C. Zeretzke et al., “Herpesviral protein networks and their interaction with the human proteome,” Science, vol. 311, no. 5758, pp. 239–242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Rozen, N. Sathish, Y. Li, and Y. Yuan, “Virion-wide protein interactions of Kaposi's sarcoma-associated herpesvirus,” Journal of Virology, vol. 82, no. 10, pp. 4742–4750, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Zheng, J. Wan, Y. G. Cho et al., “Comparison of humoral immune responses to epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray,” Journal of Infectious Diseases, vol. 204, no. 11, pp. 1683–1691, 2011. View at Publisher · View at Google Scholar
  70. A. N. Husain, T. V. Colby, N. G. Ordóñez et al., “Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 8, pp. 1317–1331, 2009. View at Google Scholar · View at Scopus
  71. D. Martino and H. I. Pass, “Integration of multimodality approaches in the management of malignant pleural mesothelioma,” Clinical Lung Cancer, vol. 5, no. 5, pp. 290–298, 2004. View at Google Scholar · View at Scopus
  72. P. Ellis, A. M. Davies, W. K. Evans, A. E. Haynes, and N. S. Lloyd, “The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline,” Journal of Thoracic Oncology, vol. 1, no. 6, pp. 591–601, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. J. M. Hillegass, A. Shukla, M. B. MacPherson, J. P. Bond, C. Steele, and B. T. Mossman, “Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1),” Journal of Toxicology and Environmental Health A, vol. 73, no. 5-6, pp. 423–436, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Roberts, C. M. Harper, I. Downie, and R. A. Burnett, “Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma: a study of thirteen antibodies,” American Journal of Clinical Pathology, vol. 116, no. 2, pp. 253–262, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Roberts, A. E. McCall, and R. A. Burnett, “Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry,” Journal of Clinical Pathology, vol. 54, no. 10, pp. 766–770, 2001. View at Google Scholar · View at Scopus
  76. M. Hosako, T. Muto, Y. Nakamura et al., “Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker,” Journal of Proteomics, vol. 75, no. 3, pp. 833–844, 2012. View at Publisher · View at Google Scholar
  77. A. Ziegler, F. Cerciello, C. Bigosch et al., “Proteomic surfaceome analysis of mesothelioma,” Lung Cancer, vol. 75, no. 2, pp. 189–196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. J. P. J. J. Hegmans, J. D. Veltman, E. T. Fung et al., “Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS,” Technology in Cancer Research and Treatment, vol. 8, no. 5, pp. 323–332, 2009. View at Google Scholar · View at Scopus
  79. J. P. J. J. Hegmans, A. Hemmes, H. Hammad, L. Boon, H. C. Hoogsteden, and B. N. Lambrecht, “Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses,” European Respiratory Journal, vol. 27, no. 6, pp. 1086–1095, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Pagès, J. Galon, M. C. Dieu-Nosjean, E. Tartour, C. Sautès-Fridman, and W. H. Fridman, “Immune infiltration in human tumors: a prognostic factor that should not be ignored,” Oncogene, vol. 29, no. 8, pp. 1093–1102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Théry, L. Zitvogel, and S. Amigorena, “Exosomes: composition, biogenesis and function,” Nature Reviews Immunology, vol. 2, no. 8, pp. 569–579, 2002. View at Google Scholar · View at Scopus
  82. J. Wolfers, A. Lozier, G. Raposo et al., “Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming,” Nature Medicine, vol. 7, no. 3, pp. 297–303, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. M. P. Bard, J. P. Hegmans, A. Hemmes et al., “Proteomic analysis of exosomes isolated from human malignant pleural effusions,” American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 1, pp. 114–121, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. J. P. J. J. Hegmans, M. P. L. Bard, A. Hemmes et al., “Proteomic Analysis of Exosomes Secreted by Human Mesothelioma Cells,” American Journal of Pathology, vol. 164, no. 5, pp. 1807–1815, 2004. View at Google Scholar · View at Scopus
  85. D. T. Archimandriti, Y. A. Dalavanga, R. Cianti et al., “Proteome analysis of bronchoalveolar lavage in individuals from metsovo, nonoccupationally exposed to asbestos,” Journal of Proteome Research, vol. 8, no. 2, pp. 860–869, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. S. H. Constantopoulos, J. A. Goudevenos, and N. Saratzis, “Metsovo lung: pleural calcification and restrictive lung function in northwestern Greece. Environmental exposure to mineral fiber as etiology,” Environmental Research, vol. 38, no. 2, pp. 319–331, 1985. View at Google Scholar · View at Scopus
  87. A. M. Langer, R. P. Nolan, S. H. Constantopoulos, and H. M. Moutsopoulos, “Association of metsovo lung and pleural mesothelioma with exposure to tremolite-containing whitewash,” The Lancet, vol. 1, no. 8539, pp. 965–967, 1987. View at Google Scholar · View at Scopus
  88. C. W. Menges, Y. Chen, B. T. Mossman, J. Chernoff, A. T. Yeung, and J. R. Testa, “A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma,” Genes and Cancer, vol. 1, no. 5, pp. 493–505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. L. L. Garland, C. Rankin, D. R. Gandara et al., “Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group study,” Journal of Clinical Oncology, vol. 25, no. 17, pp. 2406–2413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. Y. Kuramitsu, H. Miyamoto, T. Tanaka et al., “Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines,” Proteomics, vol. 9, no. 22, pp. 5078–5089, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. W. Amin, A. V. Parwani, L. Schmandt et al., “National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research,” BMC Cancer, vol. 8, article 236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. S. K. Mohanty, A. T. Mistry, W. Amin et al., “The development and deployment of Common Data Elements for tissue banks for translational research in cancer—an emerging standard based approach for the Mesothelioma Virtual Tissue Bank,” BMC Cancer, vol. 8, article 91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. D. C. Adamson, T. J. Cummings, and A. H. Friedman, “Malignant peripheral nerve sheath tumor of the spine after radiation therapy for Hodgkin's lymphoma,” Clinical Neuropathology, vol. 23, no. 5, pp. 245–255, 2004. View at Google Scholar · View at Scopus
  94. A. N. D'Agostino, E. H. Soule, and R. H. Miller, “Sarcomas of the peripheral nerves and somatic soft tissues associated with multiple neurofibromatosis (Von Recklinghausen's Disease),” Cancer, vol. 16, pp. 1015–1027, 1963. View at Google Scholar
  95. A. A. King, M. R. Debaun, V. M. Riccardi, and D. H. Gutmann, “Malignant peripheral nerve sheath tumors in neurofibromatosis 1,” American Journal of Medical Genetics, vol. 93, no. 5, pp. 388–392, 2000. View at Publisher · View at Google Scholar
  96. B. S. Ducatman, B. W. Scheithauer, and D. G. Piepgras, “Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases,” Cancer, vol. 57, no. 10, pp. 2006–2021, 1986. View at Google Scholar · View at Scopus
  97. E. Legius, D. A. Marchuk, F. S. Collins, and T. W. Glover, “Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis,” Nature Genetics, vol. 3, no. 2, pp. 122–126, 1993. View at Publisher · View at Google Scholar · View at Scopus
  98. B. Dasgupta, Y. Yi, D. Y. Chen, J. D. Weber, and D. H. Gutmann, “Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors,” Cancer Research, vol. 65, no. 7, pp. 2755–2760, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Patrakitkomjorn, D. Kobayashi, T. Morikawa et al., “Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2,” Journal of Biological Chemistry, vol. 283, no. 14, pp. 9399–9413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. G. M. Brodeur, “Neuroblastoma: biological insights into a clinical enigma,” Nature Reviews Cancer, vol. 3, no. 3, pp. 203–216, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. Q. R. Chen, Y. K. Song, L. R. Yu et al., “Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma,” Journal of Proteome Research, vol. 9, no. 1, pp. 373–382, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. F. Yu, X. Zhu, C. Feng et al., “Proteomics-based identification of spontaneous regression-associated proteins in neuroblastoma,” Journal of Pediatric Surgery, vol. 46, no. 10, pp. 1948–1955, 2011. View at Publisher · View at Google Scholar
  103. T. Simon, B. Hero, D. H. Hunneman, and F. Berthold, “Tumour markers are poor predictors for relapse or progression in neuroblastoma,” European Journal of Cancer, vol. 39, no. 13, pp. 1899–1903, 2003. View at Publisher · View at Google Scholar · View at Scopus
  104. W. M. Hsu, H. Lee, H. F. Juan et al., “Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis,” Clinical Cancer Research, vol. 14, no. 19, pp. 6237–6245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Zanini, F. Pulerà, F. Carta et al., “Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing's sarcoma,” Virchows Archiv, vol. 452, no. 2, pp. 157–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. Q. Y. He, R. Zhu, Y. Ren, P. K. H. Tam, and J. F. Chiu, “Serological protein profiling of neuroblastoma by ProteinChip SELDI-TOF technology,” Journal of Cellular Biochemistry, vol. 95, no. 1, pp. 165–172, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. J. A. Sandoval, D. J. Hoelz, H. A. Woodruff et al., “Novel peptides secreted from human neuroblastoma: useful clinical tools?” Journal of Pediatric Surgery, vol. 41, no. 1, pp. 245–251, 2006. View at Publisher · View at Google Scholar · View at Scopus
  108. J. A. Sandoval, L. E. Dobrolecki, J. Huang, J. L. Grosfeld, R. J. Hickey, and L. H. Malkas, “Neuroblastoma detection using serum proteomic profiling: a novel mining technique for cancer?” Journal of Pediatric Surgery, vol. 41, no. 4, pp. 639–646, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. J. A. Sandoval, K. E. Turner, D. J. Hoelz, F. J. Rescorla, R. J. Hickey, and L. H. Malkas, “Serum protein profiling to identify high-risk neuroblastoma: preclinical relevance of blood-based biomarkers,” Journal of Surgical Research, vol. 142, no. 2, pp. 268–274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. R. A. Egler, Y. Li, T. A. T. Dang et al., “An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring,” Proteomics, vol. 5, no. 9-10, pp. 532–541, 2011. View at Publisher · View at Google Scholar
  111. A. Urban, J. Poland, S. Bernardini et al., “A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines,” Proteomics, vol. 5, no. 3, pp. 796–804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. E. Izbicka, D. Campos, J. Marty, G. Carrizales, G. Mangold, and A. Tolcher, “Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models,” Anticancer Research, vol. 26, no. 3 A, pp. 1983–1988, 2006. View at Google Scholar · View at Scopus
  113. S. D'Aguanno, A. D'Alessandro, L. Pieroni et al., “New insights into neuroblastoma cisplatin resistance: a comparative proteomic and meta-mining investigation,” Journal of Proteome Research, vol. 10, no. 2, pp. 416–428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. X. J. Wang, Z. Sun, N. F. Villeneuve et al., “Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2,” Carcinogenesis, vol. 29, no. 6, pp. 1235–1243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. V. H. Bull, K. Rajalingam, and B. Thiede, “Sorafenib-induced mitochondrial complex i inactivation and cell death in human neuroblastoma cells,” Journal of Proteome Research, vol. 11, no. 3, pp. 1609–1620, 2012. View at Publisher · View at Google Scholar
  116. C. Vishal, J. U. Kumar, C. V. B. Swamy et al., “Repercussion of mitochondria deformity induced by anti-Hsp90 drug 17AAG in human tumor cells,” Drug Target Insights, vol. 2011, no. 5, pp. 11–32, 2011. View at Publisher · View at Google Scholar
  117. K. Motani, K. Tabata, Y. Kimura et al., “Proteomic analysis of apoptosis induced by xanthoangelol, a major constituent of Angelica keiskei, in neuroblastoma,” Biological and Pharmaceutical Bulletin, vol. 31, no. 4, pp. 618–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Hayama, K. Tabata, T. Uchiyama, Y. Fujimoto, and T. Suzuki, “Ferrearin C induces apoptosis via heme oxygenase-1 (HO-1) induction in neuroblastoma,” Journal of Natural Medicines, vol. 65, no. 3-4, pp. 431–439, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. F. Cimmino, D. Spano, M. Capasso et al., “Comparative proteomic expression profile in all-trans retinoic acid differentiated neuroblastoma cell line,” Journal of Proteome Research, vol. 6, no. 7, pp. 2550–2564, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. J. A. Sandoval, A. C. Eppstein, D. J. Hoelz et al., “Proteomic analysis of neuroblastoma subtypes in response to mitogen-activated protein kinase inhibition: profiling multiple targets of cancer kinase signaling,” Journal of Surgical Research, vol. 134, no. 1, pp. 61–67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. Q. Fang, K. Kani, V. M. Faca et al., “Impact of protein stability, cellular localization, and abundance on proteomic detection of Tumor-Derived proteins in plasma,” PLoS ONE, vol. 6, no. 7, Article ID e23090, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. N. Campostrini, J. Pascali, M. Hamdan et al., “Proteomic analysis of an orthotopic neuroblastoma xenograft animal model,” Journal of Chromatography B, vol. 808, no. 2, pp. 279–286, 2004. View at Publisher · View at Google Scholar · View at Scopus
  123. K. E. Turner, H. R. Kumar, D. J. Hoelz et al., “Proteomic analysis of neuroblastoma microenvironment: effect of the host-tumor interaction on disease progression,” Journal of Surgical Research, vol. 156, no. 1, pp. 116–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. H. R. Kumar, X. Zhong, D. J. Hoelz et al., “Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids,” Pediatric Surgery International, vol. 24, no. 11, pp. 1229–1234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. A. J. Spillane, R. A'Hern, I. R. Judson, C. Fisher, and J. M. Thomas, “Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment,” Journal of Clinical Oncology, vol. 18, no. 22, pp. 3794–3803, 2000. View at Google Scholar · View at Scopus
  126. M. Trassard, V. Le Doussal, K. Hacène et al., “Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 525–534, 2001. View at Google Scholar · View at Scopus
  127. J. Clark, P. J. Rocques, A. J. Crew et al., “Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma,” Nature Genetics, vol. 7, no. 4, pp. 502–508, 1994. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Kawai, J. Woodruff, J. H. Healey, M. F. Brennan, C. R. Antonescu, and M. Ladanyi, “SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma,” New England Journal of Medicine, vol. 338, no. 3, pp. 153–160, 1998. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Suehara, N. Tochigi, D. Kubota et al., “Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics,” Journal of Proteomics, vol. 74, no. 6, pp. 829–842, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. Y. Suehara, K. Kikuta, R. Nakayama et al., “GST-P1 as a histological biomarker of synovial sarcoma revealed by proteomics,” Proteomics, vol. 3, no. 5, pp. 623–634, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. F. M. Enzinger, “Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases,” Cancer, vol. 18, pp. 1163–1174, 1965. View at Google Scholar
  132. J. Zucman, O. Delattre, C. Desmaze et al., “EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts,” Nature Genetics, vol. 4, no. 4, pp. 341–345, 1993. View at Publisher · View at Google Scholar · View at Scopus
  133. E. B. Chung and F. M. Enzinger, “Malignant melanoma of soft parts. A reassessment of clear cell sarcoma,” American Journal of Surgical Pathology, vol. 7, no. 5, pp. 405–413, 1983. View at Google Scholar · View at Scopus
  134. H. A. Tawbi and J. M. Kirkwood, “Management of Metastatic Melanoma,” Seminars in Oncology, vol. 34, no. 6, pp. 532–545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Kawai, A. Hosono, R. Nakayama et al., “Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients,” Cancer, vol. 109, no. 1, pp. 109–116, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. K. Dimas, C. Tsimplouli, A. K. Anagnostopoulos et al., “The proteome profile of two cell lines and their xenografts isolated from a patient with clear cell sarcoma (soft tissue melanoma),” Cancer Genomics and Proteomics, vol. 5, no. 3-4, pp. 175–238, 2008. View at Google Scholar · View at Scopus
  137. A. Celis, H. H. Rasmussen, P. Celis et al., “Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities,” Electrophoresis, vol. 20, no. 2, pp. 355–361, 1999. View at Google Scholar · View at Scopus
  138. S. W. Weiss and J. R. Goldblum, “Malignant soft tissue tumors of uncertain type,” in Enzinger and Weiss's Soft Tissue Tumors, pp. 1161–1220, Elsevier Mosby, Philadelphia, Pa, USA, 2008. View at Google Scholar
  139. N. G. Ordóñez, “Alveolar soft part sarcoma: a review and update,” Advances in Anatomic Pathology, vol. 6, no. 3, pp. 125–139, 1999. View at Google Scholar
  140. F. H. Shipkey, P. H. Lieberman, F. W. Foote, and F. W. Stewart, “Ultrastructure of alveolar soft part sarcoma,” Cancer, vol. 17, pp. 821–830, 1964. View at Google Scholar
  141. K. Tsuji, Y. Ishikawa, and T. Imamura, “Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript,” Human Pathology, vol. 43, no. 3, p. 356, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. B. M. Balgley, T. Guo, K. Zhao, X. Fang, F. A. Tavassoli, and C. S. Lee, “Evaluation of archival time on shotgun proteomics of formalin-fixed and paraffin-embedded tissues,” Journal of Proteome Research, vol. 8, no. 2, pp. 917–925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. S. Meding, U. Nitsche, B. Balluff et al., “Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging,” Journal of Proteome Research, vol. 11, no. 3, pp. 1996–2003, 2012. View at Publisher · View at Google Scholar
  144. C.-Y. Chang, P. Picotti, R. Hüttenhain et al., “Protein significance analysis in selected reaction monitoring (SRM) measurements,” Molecular and Cellular Proteomics, vol. 11, no. 4, 2012. View at Publisher · View at Google Scholar
  145. T. Kondo, “Cancer proteome-expression database: genome Medicine Database of Japan Proteomics,” Expert Review of Proteomics, vol. 7, no. 1, pp. 21–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Watanabe, Y. Inoue, C. Chang et al., “For what am I participating? The need for communication after receiving consent from biobanking project participants: experience in Japan,” Journal of Human Genetics, vol. 56, no. 5, pp. 358–363, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. C. F. Taylor, N. W. Paton, K. S. Lilley et al., “The minimum information about a proteomics experiment (MIAPE),” Nature Biotechnology, vol. 25, no. 8, pp. 887–893, 2007. View at Publisher · View at Google Scholar · View at Scopus